Abstract
Hematopoietic cell transplantation is the only curative therapy available for patients with the common and morbid inherited hemoglobin disorders, -thalassemia major and sickle cell anemia. As will be discussed, a number of complex independent factors need to be carefully weighed in making a decision as to whether the patient is an appropriate candidate for hematopoietic cell transplantation (HCT). In this review, we will consider patients with -thalassemia major and -thalassemia intermedia, along with those with sickle cell anemia, and discuss options and limitations of current and future approaches to treat these hemoglobinopathies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current Problems in Pediatric and Adolescent Health Care
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
